Literature DB >> 16213598

MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo.

Olivier Benveniste1, Leslie Jacobson, Maria Elena Farrugia, Linda Clover, Angela Vincent.   

Abstract

MG is an antibody-mediated disease that is often treated with corticosteroids. Antibodies to the muscle specific tyrosine kinase (MuSK) have been identified in a proportion of patients with myasthenia gravis (MG) without acetylcholine receptor (AChR) antibodies. MuSK-MG patients often suffer from marked facial muscle weakness, and some patients develop facial and tongue muscle atrophy. MuSK is a receptor tyrosine kinase that plays an essential role during development and is thought to play a trophic role in mature muscle. It is possible, therefore, that the muscle atrophy results from the action of the MuSK antibodies themselves, but effects of corticosteroids on muscle might also be involved. Muscle atrophy in vivo is associated with upregulation of striated Muscle RING-Finger protein-1 (MURF-1), and MURF-1 is also upregulated in C2C12 myotubes exposed to the corticosteroid, dexamethasone (Dex). Here we investigated the effects of MuSK antibodies or Dex on MURF-1 expression in C2C12 cultures and in mouse muscles after treatment in vivo, using quantitative Western blotting. We also looked at expression of neural cell adhesion molecule (NCAM, CD56) that is upregulated after denervation in vivo. MuSK-MG plasma and purified IgG from a patient with marked muscle atrophy modestly increased MURF-1 expression in C2C12 cells in culture, and MURF-1 expression in mouse masseter (facial) muscle, but not in gastrocnemius (leg). Dex had a more marked effect on MURF-1 expression in C2C12 cells, but did not affect MURF-1 expression in either muscle. However, both in C2C12 cells and in vivo, Dex substantially reduced NCAM expression. These results provide the first evidence that MuSK-MG plasma can influence expression of an atrophy-related protein, and preliminary evidence that a facial muscle, the masseter, is more susceptible to this effect. They indicate the need for further studies on muscle atrophy, MuSK-MG antibodies, the effects of steroids, and the intracellular pathways involved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213598     DOI: 10.1016/j.jneuroim.2005.08.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.

Authors:  Alexandra Pevzner; Benedikt Schoser; Katja Peters; Nicoleta-Carmen Cosma; Andromachi Karakatsani; Berthold Schalke; Arthur Melms; Stephan Kröger
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 3.  Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.

Authors:  Rebecca L Hurst; Clifton L Gooch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

4.  [Neuromuscular signal transmission in adulthood. Current facets of acquired and hereditary disorders].

Authors:  A Abicht; S Kröger; B Schoser
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

5.  Very late onset AChR-myasthenia gravis with tongue atrophy.

Authors:  Vasiliki Zouvelou; Georgios Zorbas; Eleni Strataki; Efstratios Karavasilis; Georgios Velonakis
Journal:  Acta Neurol Belg       Date:  2022-03-06       Impact factor: 2.471

6.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

7.  p38 MAPK Participates in Muscle-Specific RING Finger 1-Mediated Atrophy in Cast-Immobilized Rat Gastrocnemius Muscle.

Authors:  Junghwan Kim; Kyung-Jong Won; Hwan Myung Lee; Byong-Yong Hwang; Young-Min Bae; Whan Soo Choi; Hyuk Song; Ki Won Lim; Chang-Kwon Lee; Bokyung Kim
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

8.  MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis.

Authors:  Georgios Velonakis; Vassilis E Papadopoulos; Efstratios Karavasilis; Dimitrios K Filippiadis; Vasiliki Zouvelou
Journal:  Neuroradiology       Date:  2021-07-07       Impact factor: 2.804

9.  Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies.

Authors:  Giovanna Cenacchi; Valentina Papa; Papa Valentina; Marina Fanin; Fanin Marina; Elena Pegoraro; Pegoraro Elena; Corrado Angelini; Angelini Corrado
Journal:  J Neurol       Date:  2010-11-19       Impact factor: 4.849

10.  Regenerative strategies for craniofacial disorders.

Authors:  Catharine B Garland; Jason H Pomerantz
Journal:  Front Physiol       Date:  2012-12-14       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.